Telaprevir for Retreatment of HCV Infection

Zeuzem, Stefan; Andreoné, Pietro; Pol, Stanislas; Lawitz, Eric; Diago, M.; K. Roberts, Stuart; Focaccia, Roberto; M. Younossi, Zobair; R. Foster, Graham; Horban, Andrzej; Ferenci, Peter; Nevens, Frederik; Müllhaupt, Beat; J. Pockros, Paul; Terg, Rubén; Shouval, Daniel; van Hoek, Bart; Weiland, Ola; van Heeswijk, Rolf; De Meyer, Sandra; Luo, Don; Boogaerts, Griet; Polo, Ramon; Picchio, Gastón; Beumont, Maria

doi:10.1056/nejmoa1013086

Public

Telaprevir for Retreatment of HCV Infection

Published in New England Journal of Medicine • Jun 22, 2011

Authors:

Stefan Zeuzem

Pietro Andreoné

Stanislas Pol

Abstract

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin. METHODS: In this randomized, phase 3 trial, we evaluated the addition of telaprevir to peginterferon alfa-2a plus ribaviri...

Subject

Telaprevir

Medicine

Virology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!